Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanshinone IIA sodium sulfonate for blood-brain barrier protection after rt-PA in acute ischemic stroke
ChiCTR-ONRC-14004659Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sodium tanshinone IIA sulfonate in ischemic stroke (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: NIHSS score, blood-brain barrier permeability surface and 2 more. Planned start Sep 2014; status: not yet recruiting.
02
Drugs
sodium tanshinone IIA sulfonate
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR-ONRC-14004659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-14004659.